Clinical Studies - Follow-Up Only

The following are clinical studies for which enrollment is complete, but follow-up study continues.

CORAL: This study looks at patients with renal artery stenosis and randomizes them to either have their renal artery opened by implanting a stent and receiving optimal medical therapy or receiving optimal medical therapy only. Previous studies have shown conflicting conclusions as to the risk/benefit ratio for renal artery stenting procedures. For more information contact Rita at 309-691-4410.

DURABILITY II: The Protégé Everflex Nitinol Stent is used to open blockages in the superficial femoral and proximal popliteal arteries of the legs. Data is collected on patients who receive this stent for up to three years. For more information contact Rita at 309-691-4410.

EDUCATE: A prospective multicenter trial to better understand the safety and efficacy of 12 months versus 30 months of dual antiplatelet therapy and relationship to compliance and therapy interruptions in subjects undergoing stenting procedure with Endeavor stent. For more information contact Rita at 309-691-4410.

IMPROVE IT: A clinical trial to establish the benefit and safety of Vytorin (a combination drug with zocor and zetia) versus zocor monotherapy. This trial is for patients who have had an acute coronary syndrome event and are high risk for repeat cardiovascular events. For more information contact Becky at 309-691-4410.

OPTIMISE: The purpose of this study is to evaluate the clinical response and potential to improve cardiac function by using QuickOpt® in patients with CRT-D devices. If QuickOpt® is proven to be beneficial; this method would be simpler and less costly than current methods used to optimize cardiac pacemakers. For more information contact Marsha at 309-691-4410.

RATE REGISTRY: This registry documents the prevalence of atrial fibrillation or atrial flutter after implantation of pacemakers. For more information contact Lita at 309-691-4410.

STICH: For patients who have coronary artery disease that is suitable for bypass surgery, but also have symptomatic congestive heart failure, this study is stratified three ways. 1. Medical treatment vs. CABG only. 2. Medical treatment only vs. CABG vs. CABG + SVR. 3. CABG vs. CABG + SVR. For more information contact Marsha at 309-691-4410.

TRA 2°P: SCH5303438 versus placebo, in addition to standard care for patients who have had MI or a stroke during the12 months prior to entering the study. The purpose is to prevent further events by appropriately anticoagulating the blood. For more information contact Lita at 309-691-4410.

TRA▪CER: A study to evaluate the safety and efficacy of SCH 530348 in addition to standard antiplatelet therapy following an acute coronary syndrome. For more information contact Lita at 309-691-4410.

XIENCE: A prospective multicenter trial to better understand the safety and efficacy of 12 months versus 30 months of dual antiplatelet therapy and relationship to compliance and therapy interruptions in subjects undergoing stenting procedure with Xience stent. For more information contact Lita at 309-691-4410.

ZOMAXX: In patients with stable coronary artery disease who have blockages corrected by stenting, this study compares the Abbott Zomaxx Stent to the Taxus stent. For more information contact Lita at 309-691-4410.